Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Infants with SMA type 1 born since 2016 experience better functional outcomes and life expectancy with disease-modifying treatments.

Biogen Inc. (NASDAQ:BIIB) shares tumbled to a 52-week low of $139.7, reflecting a stark downturn in the biotechnology firm's market performance. With a market capitalization of $20.38 billion and a ...

From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

Meanwhile, Biogen is facing challenges elsewhere, notably with its stalled Alzheimer's therapy Aduhelm (aducanumab) and spinal muscular atrophy treatment Spinraza (nusinersen), which is seeing ...

Ionis’ pipeline of antisense drugs is also beginning to produce results – a separate alliance with Biogen resulted in development and approval of Spinraza (nusinersen), approved for spinal ...

After hours: February 7 at 6:00:15 PM EST Loading Chart for IONS ...

As of 1:15:08 PM EST. Market Open.

Pre-market: 4:26:51 am GMT-5 ...

From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...